Therapy Directory

CAR-T clinical trials

Directory of U.S. ClinicalTrials.gov public records that list CAR-T as a study intervention. Browse CAR-T recruiting trials, filter by phase, sponsor, or location, and open the official ClinicalTrials.gov study record for each result.

ClinicalTrials.gov public records Last synced Aug 25, 2026, 6:18 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials

126

Shown on this page

Local indexed summaries

126

Local recruiting

The trial list below is retrieved from the live ClinicalTrials.gov search API for CAR-T. Results on this page are currently sorted by Recently updated.

Showing 1–12 of 126 matching trials for CAR-T.

Indexed local directory records.

Top conditions

Diffuse Large B Cell Lymphoma 10 Acute Lymphoblastic Leukemia 9 Multiple Myeloma 7 Rhabdomyosarcoma 7 Follicular Lymphoma 6 Chronic Lymphocytic Leukemia 5

Top sponsors

Memorial Sloan Kettering Cancer Center 11 City of Hope Medical Center 10 National Cancer Institute (NCI) 10 Baylor College of Medicine 8 St. Jude Children's Research Hospital 7 Medical College of Wisconsin 6

Top locations

Houston, Texas 20 Duarte, California 19 New York, New York 18 Philadelphia, Pennsylvania 12 Bethesda, Maryland 11 Seattle, Washington 11

Indexed official records

Open in full search

Conditions: Multiple Myeloma
Interventions: BCMA-TGFβ CAR-T cells (0.50 x 10^6 cells/kg), BCMA-TGFβ CAR-T cells (0.75 x10^6 cells/kg), BCMA-TGFβ CAR-T cells (1 x 10^6 cells/kg), BCMA-TGFβ CAR-T cells (2.5 x 10^6 cells/kg), Maximum tolerated dose; Biological
Lead sponsor: Medical College of Wisconsin; Other
Eligibility: 18 Years to 80 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Milwaukee, Wisconsin

Conditions: Hematological Malignancies
Interventions: GLPG CAR T-cell therapy; Genetic
Lead sponsor: Lakefront Biotherapeutics NV; Industry
Eligibility: 18 Years and older
Enrollment: 546 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2039
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Acute Lymphoblastic Leukemia, B-All
Interventions: CD22 CAR-transduced T cells, Cyclophosphamide, Fludarabine; Biological · Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 3 Years to 65 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Recurrent Acute Lymphoblastic Leukemia, Recurrent B Acute Lymphoblastic Leukemia, Recurrent B-Cell Prolymphocytic Leukemia, Recurrent Chronic Lymphocytic Leukemia, Recurrent High Grade B-Cell Lymphoma, Recurrent Indolent Non-Hodgkin Lymphoma, Recurrent Non-Hodgkin Lymphoma, Recurrent Transformed Chronic Lymphocytic Leukemia, Refactory Childhood Acute Lymphoblastic Leukemia, Refractory Acute Lymphoblastic Leukemia, Refractory B Acute Lymphoblastic Leukemia, Refractory B-Cell Prolymphocytic Leukemia, Refractory Childhood Non-Hodgkin Lymphoma, Refractory Chronic Lymphocytic Leukemia, Refractory High Grade B-Cell Lymphoma, Refractory Indolent Non-Hodgkin Lymphoma, Refractory Non-Hodgkin Lymphoma, Refractory Transformed Chronic Lymphocytic Leukemia
Interventions: Anti-CD19/CD20/CD22 CAR T-Cells, Biopsy, Biospecimen Collection, Bone Marrow Aspiration and Biopsy, Cyclophosphamide, Echocardiography, Fludarabine Phosphate, Multigated Acquisition Scan, Pheresis; Biological · Procedure · Drug
Lead sponsor: Sumithira Vasu; Other
Eligibility: 2 Years and older
Enrollment: 54 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 2
States / cities: Columbus, Ohio

Conditions: Acute Lymphoblastic Leukemia, Recurrent Acute Lymphoblastic Leukemia, Recurrent B Acute Lymphoblastic Leukemia
Interventions: CD19-CD22 CAR T cell infusion, Cyclophosphamide, Fludarabine, Mesna; Device · Drug
Lead sponsor: St. Jude Children's Research Hospital; Other
Eligibility: Up to 21 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2031
U.S. locations: 1
States / cities: Memphis, Tennessee

Conditions: Adrenocortical Cancer, Carcinoma, Clear Cell Sarcoma, Desmoplastic Small Round Cell Tumor, Ewing Sarcoma, Germ Cell Cancer, Hepatoblastoma, Malignant Peripheral Nerve Sheath Tumors, Melanoma, Neuroblastoma, Osteosarcoma, Pediatric Solid Tumor, Rhabdoid Tumor, Rhabdomyosarcoma, Soft Tissue Sarcoma, Wilms Tumor
Interventions: B7-H3 CAR T cells, Cyclophosphamide, Fludarabine, MESNA; Drug
Lead sponsor: St. Jude Children's Research Hospital; Other
Eligibility: Up to 21 Years
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2028
U.S. locations: 1
States / cities: Memphis, Tennessee

Conditions: AML/MDS, B-ALL, BPDCN, T-ALL
Interventions: CD123-CAR T, Cyclophosphamide, Fludarabine, Mesna, Rituximab; Drug
Lead sponsor: St. Jude Children's Research Hospital; Other
Eligibility: Up to 21 Years
Enrollment: 108 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2030
U.S. locations: 2
States / cities: Memphis, Tennessee

Conditions: Large B-cell Lymphoma
Interventions: CAR T-cell therapy, NT-I7; Biological · Drug
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Multiple Myeloma, Multiple Myeloma in Relapse, Refractory Multiple Myeloma
Interventions: Cyclophosphamide, Fludarabine, TriPRIL CAR T Cells; Drug
Lead sponsor: Marcela V. Maus, M.D.,Ph.D.; Other
Eligibility: 18 Years and older
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2028
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Diffuse Large B Cell Lymphoma, Non Hodgkin Lymphoma
Interventions: CAR-T cell, Iomab-B; Drug
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Acute Lymphoblastic Leukemia, Diffuse Large B Cell Lymphoma, Hematologic Malignancy, Large B-cell Lymphoma, Mantle Cell Lymphoma, Multiple Myeloma
Interventions: autologous hematopoietic stem cells added to planned CAR T; Biological
Lead sponsor: Joshua Sasine, MD, PhD; Other
Eligibility: 18 Years to 85 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Recurrent Astrocytoma, IDH-Mutant, Grade 4, Recurrent Glioblastoma, IDH-Wildtype
Interventions: Autologous Anti-EGFR/Anti-IL13Ralpha2 CAR T-cells, Biopsy Procedure, Biospecimen Collection, Echocardiography Test, FDG-Positron Emission Tomography, Intracranial Catheter Placement, Leukapheresis, Magnetic Resonance Imaging, Resection; Biological · Procedure
Lead sponsor: City of Hope Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 1
States / cities: Duarte, California

About this CAR-T clinical trials directory page

What this page lists: U.S. ClinicalTrials.gov public records that list CAR-T as a study intervention, including recruiting, not yet recruiting, and active not recruiting trials.
How to narrow results: Use the filters above to scope by condition, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, age, or NCT ID within CAR-T.
Where the data comes from: Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, ranking of trials by quality, or AI-generated medical summaries.

CAR-T clinical trials

Filter and sort this therapy

Top conditions

Top sponsors

Top locations

Indexed official records

Phase I Trial of BCMA-TGF-BETA CAR-T Cells in Relapsed, Refractory Myeloma

Long-term Follow-up of Participants Treated With Galapagos Chimeric Antigen Receptor (CAR) T-cell Therapies

CD22 CAR T-cells to Extend Remission Following Commercial CD19 CAR T-cells in Children, Adolescents, and Adults With Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia

Genetically Engineered Cells (Anti-CD19/CD20/CD22 CAR T-cells) for the Treatment of Relapsed or Refractory Lymphoid Malignancies

CD19-CD22-Bispecific Chimeric Antigen Receptor (CAR) T Cell Therapy for Pediatric Patients With Acute Lymphoblastic Leukemia

B7-H3-Specific Chimeric Antigen Receptor Autologous T-Cell Therapy for Pediatric Patients With Solid Tumors (3CAR)

CD123-Directed T-Cell Therapy for Acute Myelogenous Leukemia (CATCHAML)

NT-I7 (Efineptakin Alfa), a Long-acting Human IL-7, Post-Axicabtagene Ciloleucel or Post-Lisocabtagene Maraleucel in Subjects With Relapsed/Refractory Large B-cell Lymphoma

TriPRIL CAR T Cells in Multiple Myeloma

IOMAB-CAR-T Followed by CAR-T Cell Therapy in R/R DLBCL

Feasibility and Safety of Collecting and Combining Autologous Hematopoietic Stem Cells With Chimeric Antigen Receptor (CAR) T-Cell Therapy in Subjects With Relapsed/Refractory Hematological Malignancies

Locoregional Administration of Genetically Engineered Cells (EGFR/IL13Rα2 Pool-CAR T Cells) for the Treatment of Recurrent or Progressive High-Grade Gliomas

About this CAR-T clinical trials directory page